lifestyle.thedishh.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
IGC Pharma, Inc.
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
May 3, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
April 8, 2026
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer’s Disease
April 7, 2026
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
March 30, 2026
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
March 19, 2026
IGC Pharma to Showcase AI Platform with Alzheimer’s Disease Data Initiative at ADPD 2026
March 18, 2026
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer’s Research
February 26, 2026
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
February 24, 2026
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
February 23, 2026
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
February 18, 2026
1
2
3
Next Page
→